The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.
May 2nd 2024
Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Novel Therapies Targeting Vasoconstriction and Vascular Remodeling May Improve Outcomes in PAH
May 8th 2022Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.
Read More
Dapagliflozin Combo Is Not More Effective in Reducing PAH in Preclinical Study
April 16th 2022The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.
Read More
Enhancing Hemodynamic Parameters in Acute Decompensated Right Heart Failure in Patients With CTD-PAH
March 31st 2022Levosimendan appeared to increase in-hospital survival rates, although no long-term survival benefit was reported, among patients with comorbid heart failure and connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH).
Read More
Elevated Repolarization Dispersion Linked With LV Diastolic Discoordination in Pediatric PAH
March 12th 2022Repolarization dispersion has been linked to echocardiographic measures of diastolic dysfunction in past research, and a recent study found it potentially indicative of pulmonary arterial hypertension severity.
Read More
Review Finds Sildenafil Safe, Effective for PAH Treatment in Asian Adults
February 25th 2022Studies focused on Asian populations with pulmonary arterial hypertension (PAH) treated with sildenafil are rare, and a new meta-analysis has found the phosphodiesterase-5 inhibitor effective in this understudied subgroup.
Read More
Metabolic Differences Between Endothelial Cells in PH Phenotypes Explained
February 18th 2022This new study aimed to identify metabolic differences in endothelial cells in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (PH) to aid in the development of novel therapeutic approaches.
Read More
Routine Lung CT Reports Have Diagnostic and Prognostic Utility in Pulmonary Hypertension Subtypes
February 5th 2022Idiopathic pulmonary arterial hypertension and pulmonary hypertension due to chronic lung disease can be difficult to differentiate, but new research suggests descriptions of lung parenchyma in routine CT scans may prove useful.
Read More
Study Expands Evidence of Inheritance Pattern in GDF2 Associated With PAH
January 2nd 2022Study results regarding the clinical spectrum and inheritance pattern of GDF2 pathogenic variants suggest incomplete penetrance and/or variability of expressivity with a semi-dominant pattern of inheritance in the context of PAH.
Read More
Could GLP-1 RAs Improve COVID-19-Induced Pulmonary Arterial Hypertension?
December 30th 2021Recent studies show that glucagon-like peptide-1 receptor agonists have anti-inflammatory effects in human and rodent pathological models, making them a potential therapeutic strategy for treating pulmonary arterial hypertension after COVID-19 infection.
Read More
Top 5 Most-Read PAH Articles of 2021
December 23rd 2021This year’s most-read articles on pulmonary arterial hypertension (PAH) covered a range of topics, including nutrition, therapy switches, and patient education to improve treatment adherence. Improving patient outcomes is something they all had in common.
Read More